Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
2.970 USD   -9.17%
09/13INVIVYD, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société INVIVYD, INC.
09/13INVIVYD, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial..
AQ
09/12ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
GL
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
AQ
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
GL
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
AQ
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
AQ
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
08/15Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highligh..
GL
07/05ADAGIO THERAPEUTICS : Announces Results of Annual Meeting of Stockholders and Evolution of..
PU
07/05ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
07/05Mithril Capital's Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for..
BU
07/05Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
GL
07/01Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
GL
07/01Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
AQ
06/30ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/22ADAGIO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/21ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/13ADAGIO THERAPEUTICS : Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Control..
PU
06/13ADAGIO THERAPEUTICS : ADG20, a half-life–extended monoclonal antibody in development..
PU
05/19ADAGIO THERAPEUTICS : Material Event - Form 8-K
PU
05/19ADAGIO THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
05/13ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/13Adagio Therapeutics Reports First Quarter 2022 Financial Results
GL
04/14Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
AQ
03/31ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
03/30ADAGIO THERAPEUTICS : Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to M..
PU
03/30Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to ..
AQ
03/21ADAGIO THERAPEUTICS : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K/A
PU
03/21ADAGIO THERAPEUTICS : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K
PU
03/21ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
03/21ADAGIO THERAPEUTICS, INC. Change in Directors or Principal Officers, Financial Stateme..
AQ
03/18Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
03/18Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
03/01ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/23ADAGIO THERAPEUTICS : Announces David Hering Appointed Interim Chief Executive Officer - F..
PU
02/23ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
02/23Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
02/23Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
02/22ADAGIO THERAPEUTICS : Announces CEO Succession Plan - Form 8-K
PU
02/22ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/22Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
02/22Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
02/18Adagio Therapeutics Announces CEO Succession Plan
GL
02/18ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/13ADAGIO THERAPEUTICS : Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants a..
PU
01/13ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements a..
AQ
01/12Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
01/12Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
01/06Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ADAGIO THERAPEUTICS : Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against..
PU
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Agains..
AQ
2021ADAGIO THERAPEUTICS : Reports That None of the Mutations Present in SARS-CoV-2 Variant, Om..
PU
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, O..
AQ
2021ADAGIO THERAPEUTICS : Announces Expansion of Management Team and Board of Directors to Sup..
PU
2021ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Discl..
AQ
2021Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Su..
AQ
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2021ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021ADAGIO THERAPEUTICS : Provides Update for ADG20 COVID-19 Antibody Program and Reports Thir..
PU
2021Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Thi..
AQ
2021Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
2021ADAGIO THERAPEUTICS : Announces New In Vitro Data Highlighting Broad and Potent Neutraliza..
PU
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ADAGIO THERAPEUTICS : Announces New In Vitro Data Highlighting Broad and Potent Neutraliza..
AQ
2021ADAGIO THERAPEUTICS : ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prol..
PU
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ADAGIO THERAPEUTICS : Announces New Data Highlighting the Potential of ADG20 for Treatment..
AQ
2021ADAGIO THERAPEUTICS : to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Da..
AQ
2021ADAGIO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
1  2Next
Upcoming event on INVIVYD, INC.